Serotonin-induced contraction in canine coronary artery and saphenous vein: role of a 5-HT1D-like receptor.
The identity of the serotonin (5-HT) receptor(s) that mediate(s) contraction in canine coronary artery and saphenous vein remains controversial. Ring segments of endothelium-denuded coronary artery and helical strips of saphenous vein were suspended in organ chambers for measurement of isometric force. 5-HT, alpha Me-5-HT and sumatriptan contracted both coronary artery and saphenous vein and the non-selective 5-HT receptor antagonist 1-naphthylpiperazine (100nM) blocked 5-HT- and sumatriptan-induced contraction in both tissues. The agonist rank order potency for contraction (5-HT > sumatriptan > alpha Me5-HT > 5-MeOT > 5-MeT) was similar in both tissues and was consistent with that for a 5-HT1D receptor. Oligonucleotide primers specific for the 5-HT1D receptor sequence were designed for use in a polymerase chain reaction (PCR). cDNA derived from total RNA or mRNA from canine tissues was used in the PCR. PCR resulted in the amplification of a 632 base pair sequence in both canine coronary artery and saphenous vein; consistent with that expected for the 5-HT1D receptor. Southern blot analysis, with an oligonucleotide probe internal to the sequence amplified by the PCR primers, confirmed that the sequence amplified by PCR was the 5-HT1D receptor. Thus, the 5-HT1D receptor is expressed in canine coronary artery and saphenous vein and taken together with the pharmacological data, supports the possibility that a 5-HT1D-like receptor mediates contraction in these two tissues.
Cushing
D J
DJ
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285.
Baez
M
M
Kursar
J D
JD
Schenck
K
K
Cohen
M L
ML
D008735:5-Methoxytryptamine / Q000494:pharmacology; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D001483:Base Sequence; D015139:Blotting, Southern; D003331:Coronary Vessels / Q000187:drug effects / Q000502:physiology*; D017931:DNA Primers / Q000737:chemistry; D004146:Dioxanes / Q000494:pharmacology; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D015870:Gene Expression; D019329:Idazoxan; D008969:Molecular Sequence Data; D009119:Muscle Contraction / Q000187:drug effects*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000502:physiology*; D010879:Piperazines / Q000494:pharmacology; D016133:Polymerase Chain Reaction; D011224:Prazosin / Q000494:pharmacology; D012333:RNA, Messenger / Q000032:analysis; D011985:Receptors, Serotonin / Q000235:genetics / Q000502:physiology*; D012501:Saphenous Vein / Q000187:drug effects / Q000502:physiology*; D012701:Serotonin / Q000031:analogs & derivatives / Q000494:pharmacology / Q000502:physiology; D017366:Serotonin Receptor Agonists / Q000494:pharmacology; D018170:Sumatriptan / Q000494:pharmacology; D014363:Tryptamines / Q000494:pharmacology
D000317:Adrenergic alpha-Antagonists; D017931:DNA Primers; D004146:Dioxanes; D010879:Piperazines; D012333:RNA, Messenger; D011985:Receptors, Serotonin; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; C027552:5-methyltryptamine; C042390:alpha-methylserotonin; D012701:Serotonin; D008735:5-Methoxytryptamine; C048241:1-(1-naphthyl)piperazine; D018170:Sumatriptan; C047087:5-carboxamidotryptamine; D011224:Prazosin; D019329:Idazoxan